Centessa Pharmaceuticals (CNTA): Analysts Initiate With 'Buy' on 'Broad Pipeline With Significant Optionality'
Tweet Send to a Friend
Wall Street analysts have kicked off coverage of Centessa Pharmaceuticals (NASDAQ: CNTA) with a rating equivalent to “Buy.” So far ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
